FDA Promises Imminent Guidance On Interchangeable Biosimilar Exclusivity

Planned List For 2025 Also Includes Numerous Other Generics Guidances

 
• By Dave Wallace
  
The FDA has set out its 2025 list of planned guidances (Shutterstock)

More from Regulation

More from Generics Bulletin